Hidetomo Kikuchi

Dr. Hidetomo Kikuchi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2009 in Cancer Letters
Verified
Journal Article
Closed access
PDF file
MIMasahiko Imai
Masahiko Imai
HKHidetomo Kikuchi
Hidetomo Kikuchi
TDTakanori Denda
Takanori Denda
KOKunio Ohyama
Kunio Ohyama
CHChieko Hirobe
Chieko Hirobe
HTHiroo Toyoda
Hiroo Toyoda


20 September 2013 in International Journal of Oncology
Verified
Journal Article
Closed access
HKHidetomo Kikuchi
Hidetomo Kikuchi
BYBo Yuan
Bo Yuan
EYEisuke Yuhara
Eisuke Yuhara
NTNorio Takagi
Norio Takagi
HTHiroo Toyoda
Hiroo Toyoda
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

9 October 2013 in International Journal of Oncology
Verified
Journal Article
Closed access
HKHidetomo Kikuchi
Hidetomo Kikuchi
BYBo Yuan
Bo Yuan
YNYoshio Nishimura
Yoshio Nishimura
MIMasahiko Imai
Masahiko Imai
RFRyota Furutani
Ryota Furutani
HTHiroo Toyoda
Hiroo Toyoda
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

21 May 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
HKHidetomo Kikuchi
Hidetomo Kikuchi
BYBo Yuan
Bo Yuan
EYEisuke Yuhara
Eisuke Yuhara
MIMasahiko Imai
Masahiko Imai
RFRyota Furutani
Ryota Furutani
HTHiroo Toyoda
Hiroo Toyoda
We have demonstrated that an extract from the ripe fruit of Vitex angus-castus (Vitex), might be a promising anticancer candidate. In order to further provide a molecular rationale for clinical development in anticancer therapy, a detailed mechanism underlying the efficacy of Vitex against HL-60 cells was investigated. Vitex induced a dose- and time-dependent decrease in cell viability associated with induction of apoptosis and G(2)/M cell cycle arrest, both of which were suppressed by the addition of SB203580, an inhibitor for p38 MAPK. Furthermore, SB203580 significantly suppressed Vitex-induced phosphorylation of histone H3, a downstream molecule of p38 MAPK known to be involved in apoptosis induction in tumor cells. Notably, Vitex induced upregulation of intracellular ATP, known to bind its binding pocket inside activated p38 MAPK and to be required for the activation of p38 MAPK pathway. These results, thus, suggest that upregulation of intracellular ATP and phosphorylation of histone H3 are closely associated with the activation of p38 MAPK pathway, consequently contributing to Vitex-mediated cytotoxicity. Intriguingly, a significant decrease of intracellular ROS levels and downregulation of expression level of gp91(phox), an important component of NADPH oxidase, were observed in Vitex-treated cells. A greater decline in ROS levels along with enhanced apoptosis was observed after treatment with Vitex in combination with SnPP, an inhibitor specific for HO-1. Since NADPH oxidase and HO-1 are closely correlated to redox status associated with intracellular ROS levels, the two enzymes are suggested to be implicated in Vitex-mediated cytotoxicity in HL-60 cells by regulating ROS generation. We also suggest that activation of the p38 MAPK pathway may be dependent on the alterations of intracellular ATP levels, rather than that of intracellular ROS levels. These results may have important implications for appropriate clinical uses of Vitex and provide novel insights into the interaction between Vitex and other conventional drugs capable of affecting intracellular redox status.

1 October 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
YYYuta Yoshino
Yuta Yoshino
BYBo Yuan
Bo Yuan
SOSaki Okusumi
Saki Okusumi
RAReiji Aoyama
Reiji Aoyama
RMRyo Murota
Ryo Murota
HTHiroo Toyoda
Hiroo Toyoda